Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12258346-B2

Patent

Publication Date

2025-03-25

Expiration Date


Abstract

The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

Core Innovation

The disclosure relates to compounds selected from the group consisting of the compounds of Formula I, Formula II, Formula IIa, Formula IIb, Formula III, Formula IV, and variants including Formulas IVa, IVb, and IVc, together with pharmaceutically acceptable salt forms thereof. It includes substituted indolinone, pyrrolopyridinone, and imidazo[4,5-c]pyridine-containing compounds, with boronic acid and boronate intermediates and related derivative series.

The disclosure further describes substituted benzamide and spirocyclic heteroaromatic intermediates, including 5-bromo-substituted N-alkyl/aryl-2-methylbenzamides and related benzamide derivatives bearing substituents such as 2-methoxyethyl, trifluoromethoxy, trifluoromethyl, cyclopropyl, ethyl, and fluoro. It also includes spiro[azetidine-3,3′-indolin]-2-one derivatives, boronic ester-containing spiroindoline compounds, 1′-acyl derivatives, and oxetane-containing analogs, together with substituted amine and bicyclic ring variants.

The described content ties the chemical entities to formula-defined scope and to downstream pharmaceutical composition and therapeutic method claims. It includes preparation of substituted compounds through Pd-catalyzed coupling, Miyaura borylation to pinacol boronates, and related transformations, with intermediate borylated or brominated precursors used to access the reported compound families.

Claims Coverage

The consolidated claim coverage centers on compound scope defined either by selection from a stated group or by chemical formula, with pharmaceutically acceptable salts included throughout. Across the provided claim families, the recurring inventive features are compound/formula selection, pharmaceutical composition embodiments with excipients or carriers and optional additional therapeutic agents, and therapeutic method claims directed to inhibiting hematopoietic progenitor kinase 1 (HPK1) activity, treating cancer, and increasing T-cell activation.

Selected compound or pharmaceutically acceptable salt

A compound selected from the group consisting of the claimed compounds, or a pharmaceutically acceptable salt thereof.

Compound of a formula or pharmaceutically acceptable salt

A compound of formula, or a pharmaceutically acceptable salt thereof.

Pharmaceutical composition with excipient or carrier

A pharmaceutical composition comprising the compound of the claims (or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable excipient or carrier.

Pharmaceutical composition with one or more additional therapeutic agents

The pharmaceutical composition further comprising one or more additional therapeutic agents, or a pharmaceutically acceptable salt thereof.

Inhibiting HPK1 activity by administration

A method of inhibiting hematopoietic progenitor kinase 1 (HPK1) activity in a subject in need thereof by administering a therapeutically effective amount of the compound (or its pharmaceutically acceptable salt) or the pharmaceutical composition.

Treating cancer by administration

A method of treating a cancer in a subject in need thereof by administering a therapeutically effective amount of the compound (or its pharmaceutically acceptable salt) or the pharmaceutical composition.

Increasing T-cell activation by administration

A method of increasing T-cell activation in a subject in need thereof by administering a therapeutically effective amount of the compound (or its pharmaceutically acceptable salt) or the pharmaceutical composition.

Overall, the claims cover compound scope defined by group selection and formula-based embodiments, including pharmaceutically acceptable salts, and extend to pharmaceutical compositions and administration-based therapeutic methods for HPK1 activity inhibition, cancer treatment, and increased T-cell activation.

Stated Advantages

Inhibiting hematopoietic progenitor kinase 1 (HPK1) activity in a subject.

Treating cancer in a subject.

Increasing T-cell activation in a subject.

Documented Applications

Inhibiting hematopoietic progenitor kinase 1 (HPK1) activity in a subject by administering a therapeutically effective amount of the compound or pharmaceutical composition.

Treating cancer in a subject by administering a therapeutically effective amount of the compound or pharmaceutical composition.

Increasing T-cell activation in a subject by administering a therapeutically effective amount of the compound or pharmaceutical composition.

Combination antiretroviral HIV treatment regimens, including combinations and drug-class exemplars.

Cancer/hyper-proliferative disease combination therapy using broad classes of anticancer agents and additional therapeutic modalities.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.